rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Protects the Stomach From Damage Caused by the Diabetes Drug Alloxan

RPEP-005511999Petek, M; Sikiric, P; Anic, T; Buljat, G; Separovic, J; Stancic-Rokotov, D; Seiwerth, S; Grabarevic, Z; Rucman, R; Mikus, D; Zoricic, I; Prkacin, I; Sebecic, B; Ziger, T; Coric, V; Turkovic, B; Aralica, G; Rotkvic, I; Mise, S; Hahn, V
Animal StudyPreliminary evidence
The takeaway

BPC-157 significantly reduced and accelerated healing of stomach ulcers caused by alloxan (a diabetogenic agent) in both rats and mice, with effects lasting throughout the observation period.

Both species protected

BPC-157 reduced alloxan-induced gastric lesions in both rats and mice, showing consistent gastroprotection across species

What the researchers found

BPC-157 significantly attenuated alloxan-induced gastric lesions in rats (200 mg/kg SC) and mice (400 mg/kg IP), reducing lesion severity and accelerating healing over the observation period.

Why it matters

Diabetic patients often develop gastropathy (stomach problems). A peptide that protects the stomach from chemical-induced damage relevant to diabetes could have therapeutic applications for diabetic gastrointestinal complications.

How the study worked

Animal study in rats and mice. Alloxan was administered to induce gastric lesions and diabetes. BPC-157 was given IP. Gastric lesions were scored at 24 hours and later timepoints.

What this study cannot tell us

Animal study using alloxan, which is not used clinically and may not perfectly model diabetic gastropathy. The mechanism of gastroprotection was not elucidated.

How to read the evidence

Preliminary animal evidence in two species showing consistent gastroprotective effects, but limited by the alloxan model's clinical relevance.

When this study was published

Published in 1999. BPC-157's gastroprotective effects have been further documented across numerous insult models.

The bigger picture

BPC-157's gastroprotective effects extend beyond simple ulcer healing to protecting against chemical toxicity. This broadens its potential applications to medication-induced and disease-related stomach damage.

Questions still open

  • Does BPC-157 protect against other medication-induced gastropathy?
  • Could BPC-157 help diabetic patients with gastric complications?
  • What is BPC-157's mechanism of gastroprotection against chemical agents?

Common questions

What is BPC-157's gastroprotective effect?
BPC-157, derived from a stomach protein, has been shown to protect the stomach lining from damage caused by various agents. In this study, it protected against chemical damage from alloxan, a substance that also induces diabetes.
Is this relevant to diabetes?
Potentially. Diabetic patients often develop stomach problems. If BPC-157 can protect the stomach from diabetes-related damage (not just alloxan-specific damage), it could help manage diabetic gastrointestinal complications.

Read the original research

Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.

Journal of physiology, Paris, 93(6), 501-4

View on PubMed ↗

Citation

Petek, M; Sikiric, P; Anic, T; Buljat, G; Separovic, J; Stancic-Rokotov, D; Seiwerth, S; Grabarevic, Z; Rucman, R; Mikus, D; Zoricic, I; Prkacin, I; Sebecic, B; Ziger, T; Coric, V; Turkovic, B; Aralica, G; Rotkvic, I; Mise, S; Hahn, V. (1999). Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.. Journal of physiology, Paris, 93(6), 501-4.